Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Darzalex - labeled renal guidance
Product / population
Daratumumab (Darzalex), IV infusion
Renal method
Renal impairment categories as defined by the cited product label
All record notes are retained here, including notes about sources not selected in this review.
Darzalex - product and source limitations
Verify the presentation. Intravenous daratumumab and the subcutaneous daratumumab/hyaluronidase combination have different administration instructions.
What to reconcile: Apply only to the stated formulation, indication and renal population.
DailyMed / product prescribing information · Daratumumab (Darzalex), IV infusion
Renal method: Renal impairment categories as defined by the cited product label Source date: DailyMed SPL version 46, posted Sep 24, 2026 Retrieved: 2026-11-07
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
Renal guidance: Prescribing information, renal precautions and clinical pharmacology
Renal impairment had no clinically important effect on daratumumab disposition in the cited population analysis. Verify the presentation. Intravenous daratumumab and the subcutaneous daratumumab/hyaluronidase combination have different administration instructions.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
